Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
Environmental stimuli, such as organ-specific growth factors, can influence the metastatic potential of a tumor. The liver is the main source of insulin-like growth factors (IGFs). The importance of IGF signal in hepatic metastasis has been clarified mainly by IGF-I receptor targeting strategies. This study aims to confirm these precedent reports by novel tool, neutralizing antibodies against IGFs and to show that IGFs are promising therapeutic targets for hepatic metastasis in vivo. Hepatic metastasis was induced by intrasplenic injection of human colorectal cancer cell line, HT29. The antimetastatic effects of three antibodies (anti-mouse IGF-I, anti-mouse IGF-II, and anti-human/mouse IGF-II designated KM1468) were tested singly or in combination in the early phase of metastasis. The dose escalation effect of KM1468 and its survival benefit were examined in the early and late phases of metastasis. The mechanism of IGF neutralization was investigated with immunohistochemistry. Dual neutralization of paracrine IGF-I and IGF-II showed modest additive antimetastatic effects than single neutralization of IGF-I or IGF-II. In any phase of metastasis, neutralization led to significant tumor growth inhibition and longer survival. Dose escalation of KM1468 influenced survival only in the late phase of metastasis. Apoptosis increased significantly in the antibody-treated group compared with the control group (P = 0.0025) In conclusion, IGFs are promising therapeutic targets for hepatic metastases of colorectal cancers. However, the IGF dependency is probably variable in the metastatic process.
Miyamoto
Shin'ichi
S
Pathology Division, National Cancer Center Research Institute East, Chiba, Japan.
Nakamura
Michio
M
Shitara
Kenya
K
Nakamura
Kazuyasu
K
Ohki
Yuji
Y
Ishii
Genichiro
G
Goya
Masato
M
Kodama
Keiji
K
Sangai
Takafumi
T
Maeda
Hiroyuki
H
Shi-Chuang
Zhang
Z
Chiba
Tsutomu
T
Ochiai
Atsushi
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019073:HT29 Cells; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000276:immunology; D007335:Insulin-Like Growth Factor II / Q000276:immunology; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009500:Neutralization Tests; D013002:Somatomedins / Q000276:immunology*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II